Neuren Pharmaceuticals Limited

NEU

NZNEUE0001S8

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 02:10:51 2024-05-20 am EDT			5-day change	1st Jan Change
21.01 ^AUD	-0.38%		+10.23%	-15.86%

May. 09	Neuren Pharmaceuticals Partner Acadia Pharmaceuticals Posts US DAYBUE Sales of $75.9 Million	MT
Apr. 24	Neuren Pharmaceuticals Posts AU$243 Million Cash, Short-Term Investments	MT

Neuren Pharmaceuticals Limited Appoints Clive Blower as Vice-President of Product Development and Technical Affairs

June 22, 2014 at 08:07 pm EDT

Neuren Pharmaceuticals Limited announced that Dr. Clive Blower will join the leadership team as Vice-President: Product Development and Technical Affairs, based in Melbourne Australia, effective 25 August 2014. This appointment supports Neuren's strategy to optimise the technical attributes, manufacturing process and commercial product supply of its lead drug NNZ-2566 as it progresses towards the final stages of development. Clive is currently Chief Operating Officer of Acrux where he has been a member of the senior management team for seven years.

Latest news about Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Partner Acadia Pharmaceuticals Posts US DAYBUE Sales of $75.9 Million	May. 09	MT
Neuren Pharmaceuticals Posts AU$243 Million Cash, Short-Term Investments	Apr. 23	MT
Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada	Apr. 22	MT
Neuren Pharmaceuticals Limited Provides Sales Guidance for the First Quarter and Full Year 2024	Feb. 29	CI
Transcript : Neuren Pharmaceuticals Limited, Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
Neuren Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Culper Research discloses short position in Acadia Pharma	Feb. 15	RE
Neuren Pharmaceuticals Completes Recruitment for Phase Two Neurological Trial; Shares Fall 4%	Dec. 19	MT
Neuren Pharmaceuticals Concludes Enrollment for Phase 2 Trial in Pitt Hopkins Syndrome	Dec. 04	MT
Argenica Therapeutics Appoints Nonexecutive Chair	Nov. 29	MT
Neuren Pharmaceuticals Posts Higher Q3 Net Sales in US for Rett Syndrome Treatment	Nov. 03	MT
Neuren Pharmaceuticals Limited(ASX:NEU) added to S&P/ASX 200 Index	23-09-18	CI
Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023	23-08-27	CI
Neuren Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-27	CI
Sector Update: Health Care Stocks Gain Pre-Bell Friday	23-07-14	MT
Sector Update: Health Care	23-07-14	MT
Top Premarket Gainers	23-07-14	MT
ACADIA Pharma Acquires Ex-North America Rights to Trofinetide, Global Rights to NNZ-2591; Shares Surge Premarket	23-07-14	MT
Weaker-than-Expected US Data Spur Rally in Australian Shares	23-07-14	MT
Neuren Pharmaceuticals Jumps 17% After Global Expansion of DAYBUE Partnership	23-07-13	MT
ACADIA Pharmaceuticals Acquires Ex-North America Rights to Trofinetide, Global Rights to NNZ-2591; Shares Rise After Hours	23-07-13	MT
Neuren Pharmaceuticals' License Partner Launches Neurological Drug in the US	23-04-18	MT
Neuren Pharmaceuticals Limited(ASX:NEU) dropped from S&P/ASX Emerging Companies Index	23-03-20	CI
Neuren Pharmaceuticals' Partner Secures US FDA Approval for Rett Syndrome Treatment	23-03-13	MT
U.S. FDA approves Acadia's Rett syndrome drug (March 10)	23-03-10	RE

Chart Neuren Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Companyâs product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of trofinetide.

Sector

Pharmaceuticals

Calendar

2024-05-28 - Annual General Meeting

Related indices

S&P/ASX 200

More about the company

Income Statement Evolution

More financial data

Ratings for Neuren Pharmaceuticals Limited

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

21.09 AUD

Average target price

26.13 AUD

Spread / Average Target

+23.90%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NEUREN PHARMACEUTICALS LIMITED	-15.86%	1.8B
ELI LILLY AND COMPANY	+32.09%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-1.34%	372B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+7.39%	294B
ASTRAZENECA PLC	+13.77%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+8.49%	168B

Other Pharmaceuticals